Overview The Genome Valley Excellence Award 2026 will be conferred at the annual BioAsia Life Sciences conference in Hyderabad to Dr. Bruce Levine , Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania. The award ceremony is part of a two‑day event commencing on 17 February 2026 under the theme ‘ TechBio Unleashed: AI, Automation and the Biology Revolution ’. Dr. Levine’s pioneering work in CAR‑T cell therapy and gene editing has reshaped cancer treatment and set new standards for translational biomedical research, as highlighted by the organisers and Telangana’s Industries and IT Minister D. Sridhar Babu . Key Developments Development 1: The Genome Valley Excellence Award 2026 is presented to Dr. Bruce Levine for his outstanding contributions to cell and gene therapy, especially engineered T‑cells and cancer immunotherapy. Development 2: Dr. Levine’s research enabled safe genetic modification of human cells, laying the scientific foundation for a new generation of personalised, living medicines and directly influencing the first FDA‑approved gene therapies for cancer. Development 3: BioAsia 2026, beginning on 17 February 2026 , will explore how Artificial Intelligence (AI) , advanced biology and intelligent manufacturing converge to transform drug discovery, development and delivery worldwide. Important Facts Fact 1: Dr. Levine holds the Barbara and Edward Netter Professorship at the University of Pennsylvania Perelman School of Medicine and is internationally recognised for his work on CAR‑T and gene‑editing platforms. Fact 2: The BioAsia conference, a flagship event for India’s biotech ecosystem, is supported by the Telangana government, underscoring the state’s commitment to fostering cutting‑edge life‑science research and industry. UPSC Relevance This development intersects with several UPSC syllabus areas: Science & Technology (advances in biotechnology, gene therapy, AI in health), Health (cancer immunotherapy, personalized medicine), Economic Development (role of biotech clusters like Genome Valley in regional growth), and Governance & Policy (government support for biotech, regulatory frameworks for gene therapies). Potential questions may ask about the impact of AI on drug discovery, the ethical‑legal challenges of gene editing, or the contribution of biotech hubs to India’s innovation ecosystem. Way Forward India should leverage the momentum created by awards such as the Genome Valley Excellence Award to strengthen public‑private partnerships, streamline regulatory pathways for advanced therapies, and invest in AI‑driven research infrastructure. Policy recommendations include expanding funding for translational research, establishing clear ethical guidelines for gene editing, and promoting skill development to create a workforce capable of sustaining the biotech revolution.